Business Wire

Austrian Broadband Operator Deploys Vecima’s Entra ® vCMTS and Remote PHY Devices to Advance its Next-Generation DOCSIS ® Network

13.5.2026 13:45:00 CEST | Business Wire | Press Release

Share

Vecima Networks Inc. (TSX: VCM) and Witke today announced that an Austrian broadband operator is deploying the Entra® virtualized Cable Modem Termination System (vCMTS) as the DOCSIS® platform for its Distributed Access Architecture (DAA) evolution. The deployment, led by Witke, enables advanced reliability, scalable capacity expansion over time, and a clear migration path toward DOCSIS 4.0 broadband services.

After extensive system planning and evaluation, the operator selected a vCMTS and Remote PHY (R-PHY) architecture to align with its long-term network roll-out strategy and migration requirements. The deployment provides the flexibility to modernize the network in phases while reducing space, power, and cooling requirements across the operator’s infrastructure.

Entra vCMTS establishes a new standard for simplified, virtualized Cable Access, combining a modern microservices architecture with commercial off-the-shelf (COTS) hardware to deliver next-generation flexibility while enhancing reliability and performance. The result is a high-density, low-power, modernized platform and a resilient, stable foundation for the long-term evolution of DOCSIS.

Initially, the operator had evaluated a Remote MACPHY approach; however, detailed system planning determined that a Remote PHY architecture was better suited to its migration scenario and operational objectives. The operator selected Vecima based on its technological leadership, cloud-native architecture, and open-platform approach that supports interoperability with third-party Remote PHY Devices (RPDs), including equipment from Teleste, its primary RF electronics supplier.

The migration strategy follows a carefully planned two-step approach:

  • Phase one focuses on reusing existing HFC and headend infrastructure to accelerate deployment and minimize disruption
  • Phase two transitions the network toward Remote PHY nodes in the field as part of the operator’s long-term DAA evolution

The deployment also prioritizes operational visibility and manageability, allowing the operator to continue leveraging existing monitoring and management tools while expanding capabilities through the advanced telemetry, dashboards, and automation features integrated into the Entra vCMTS platform.

A rapid progression from lab validation to commercial deployment was achieved through the support of Witke, and these key benefits of the Entra vCMTS:

Flexible Deployment

  • Entra vCMTS integrates easily into existing and new environments thanks to flexible network configuration and monitoring options
  • Architectural support is available for both centralized and distributed deployment models
  • Options are available for a wide range of CPU densities and cluster sizes
  • Server hardware has a long service life and allows for mixed hardware generations to be active within a single cluster

Simplified Drop-in Style Configuration and Use:

  • VCMOS (Vecima’s own secure Host OS) simplifies server installation and cluster expansion
  • A familiar set of CLI commands is available for configuration and monitoring, with full support for legacy monitoring solutions
  • Automation unlocked through API/CLI equivalency and streaming telemetry
  • System health visualization and dashboards are integrated directly into the vCMTS cluster with important metrics and troubleshooting details always available

Entra vCMTS works seamlessly across Vecima’s Remote PHY portfolio and with a growing list of third-party equipment. Entra delivers true architectural flexibility across a range of network architectures and routing protocols, and from centralized RPD shelf-based deployments to those based on high-performance Distributed Access nodes. With Vecima’s approach, operators gain a flexible, efficient path to scale multi-gigabit broadband services across their business.

“We’re seeing strong demand from European operators looking to virtualize access infrastructure while preserving existing HFC investments,” said Peter Werner, Technical Manager, Broadband and Broadcast, Witke. “The Entra vCMTS combines operational flexibility with proven DOCSIS performance, giving operators a pragmatic path to distributed access architectures, higher broadband capacity, and long-term network evolution. What stood out was how quickly we moved from lab validation to live traffic.”

"As broadband traffic keeps climbing, operators need software-based architectures that scale efficiently without sacrificing performance," said Ryan Nicometo, Senior Vice President and General Manager, Broadband Networks at Vecima. "Entra vCMTS delivers exactly that — a fully virtualized, cloud-native platform that combines centralized intelligence, distributed access at the network edge, and built-in operational automation. This deployment shows how operators can modernize their HFC networks today and lay a future-ready foundation for DOCSIS 4.0, all through Vecima's proven, flexible, and simplified approach."

About Witke

What began in 1984 as a small business in a family home grew to become one of the most successful companies in Austria’s cable communication products and services market. Even with all its success, Witke remains family run, now in its second generation, with many of its roughly 90 employees having been with the company for decades. Witke’s services include electrical engineering, fiber optics, cable TV and broadcasting technology, communications, manufacturing, and construction. Where others cannot find a solution, we’re always happy to help. Visit witke.com to learn more about our services and how we can help your business succeed.

About Vecima Networks

Vecima Networks Inc. (TSX: VCM) is leading the global evolution to the multi-gigabit, content-rich networks of the future. Our talented people deliver future-ready software, services, and integrated platforms that power broadband and video streaming networks, monitor and manage transportation, and transform experiences in homes, businesses, and everywhere people connect. We help our customers evolve their networks with cloud-based solutions that deliver ground-breaking speed, superior video quality, and exciting new services to their subscribers. There is power in connectivity – it enables people, businesses, and communities to grow and thrive. Learn more at vecima.com.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of applicable Canadian securities laws. Forward-looking statements include, but are not limited to, statements regarding Vecima’s business strategies and objectives, and the anticipated benefits, performance, capabilities, availability, or adoption of its products and services. Such statements reflect current expectations and assumptions about future events and are subject to risks and uncertainties. Vecima undertakes no obligation to update any forward-looking statements unless required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260513190181/en/

Contacts

Investor Relations: 250-881-1982, invest@vecima.com
Media Relations: bernadette.dunn@vecima.com
Vecima Sales: sales@vecima.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press Release

OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press Release

Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press Release

Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als

Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press Release

Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til

IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press Release

IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, strategy, and business transformation. She most recently served as Global Head of Deloitte Digital and previously held senior global leadership roles,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye